9/17/2021  10:10:00 PM Chg. -2.02 Volume Bid2:00:00 AM Ask11:29:45 PM Market Capitalization Dividend Y. P/E Ratio
136.15USD -1.46% 2.76 mill.
Turnover: 323.25 mill.
115.00Bid Size: 100 143.88Ask Size: 100 22.87 bill.USD 0.00% 43.22

Business description

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs approximately 15,000 people, including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey.
 

Management board & Supervisory board

CEO
John Chiminsky
Management board
Thomas Castellano, Alessandro Maselli, Dr. Aris Gennadios, Jonathan Arnold, Karen Flynn, Kay Schmidt, Mike Grippo, Ricardo Pravda, Ricci Whitlow, Scott Gunther, Steven Fasman
Supervisory board
John Chiminsky, Dr. Christa Kreuzburg, Dr. Donald E. Morel, Gregory T. Lucier, J. Martin Carroll, Jack Stahl, John Greisch, Madhavan Balachandran, Michael Barber, Peter Zippelius, Rolf Classon, Rosemary Crane
 

Company data

Name: Catalent Inc.
Address: 14 Schoolhouse Road,Somerset, New Jersey 08873, USA
Phone: +1-732-537-6200
Fax: -
E-mail: -
Internet: https://www.catalent.com/
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 6/30
Free Float: -
IPO date: -

Investor relations

Name: Paul Surdez
IR phone: +1-732-537-6325
IR Fax: +1-732-537-5932
IR e-mail: investors@catalent.com

Main Shareholders

Freefloat
 
59.00%
T. Rowe Price Associates, Inc.
 
13.80%
Janus Henderson Group plc
 
10.00%
BlackRock, Inc.
 
8.90%
The Vanguard Group
 
8.30%